Monitor Clene's cash burn rate and progress on the NDA submission for CNM-Au8. The company will likely need additional capital before mid-Q1 2027, and any delays in regulatory milestones could accelerate the need for further dilutive financing.
Price Chart
Executive Summary
Clene Inc. entered into a securities purchase agreement for a $4.0 million registered direct offering of 1,219,513 shares at $3.28 per share, led by the Chairman, CEO, and other insiders. The proceeds are expected to fund operations through mid-first quarter 2027, extending the cash runway for its NDA submission for CNM-Au8 in ALS. This capital raise follows a prior $4.0 million offering on the same day, highlighting ongoing cash needs for a clinical-stage biotech with a going-concern warning.
Key Facts
- Clene raised $4.0 million in gross proceeds via a registered direct offering of 1,219,513 shares at $3.28 per share.
- The offering was led by Chairman David Matlin, founding investor Kensington Capital Holdings, CEO Robert Etherington, and other existing shareholders.
- Proceeds are expected to fund operations only through mid-first quarter 2027, indicating a cash runway of roughly 6 months.
- The company had only $9.7 million in cash as of June 30, 2026, and a going-concern warning was previously disclosed.
- This offering adds approximately 9.4% dilution to existing shareholders, based on the prior share count.
- The offering was made without a placement agent, underwriter, broker, or dealer, reducing transaction costs.
Financial Impact
$4.0 million gross proceeds, adding ~9.4% dilution to existing shareholders; cash runway extended to mid-Q1 2027
Risk Factors
- Cash runway only through mid-Q1 2027; further dilutive offerings likely needed.
- Clinical-stage biotech with no approved products; NDA approval for CNM-Au8 is uncertain.
- Going-concern warning indicates material doubt about ability to continue as a going concern.
- Insider-led offering may signal limited external investor appetite at current terms.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-030581 |
| Exhibit: ex_1016807.htm | 0001437749-26-030581 |
| Exhibit: ex_1016806.htm | 0001437749-26-030581 |
| Document: clnn20260915_8k.htm | 0001437749-26-030581 |
| Document: 0001437749-26-030581-index-headers.html | 0001437749-26-030581 |
| Document: 0001437749-26-030581-index.html | 0001437749-26-030581 |
| Document: 0001437749-26-030581.txt | 0001437749-26-030581 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $3.73 | awaiting T+20 | — | $3.88 (+4.02%) |
Oct 19, 2026 7d ago | 8-K | $3.29 | awaiting T+20 | — | $3.88 (+17.93%) |
Oct 19, 2026 7d ago | Press Release | $3.29 | awaiting T+20 | — | $3.88 (+17.93%) |
Oct 13, 2026 13d ago | SC 13G/A | $3.39 | awaiting T+20 | — | $3.88 (+14.45%) |
Sep 16, 2026 5w ago | 8-K | $4.15 $3.31 | ▲ +20.36% | ▲ +21.57% | $3.88 (+6.51%) |
Sep 16, 2026 5w ago | 424B5 | $3.86 $3.31 | ▲ +14.25% | ▲ +16.31% | $3.88 (−0.52%) |
Aug 14, 2026 10w ago | 8-K | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.88 (−6.28%) |
Aug 14, 2026 10w ago | Press Release | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.88 (−6.28%) |
Aug 10, 2026 11w ago | 8-K | $5.16 $3.62 | ▼ −29.84% | ▼ −28.93% | $3.88 (−24.81%) |
May 14, 2026 23w ago | 8-K | $7.05 $5.84 | ▼ −17.16% | ▼ −16.30% | $3.88 (−44.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers